Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(80 sites)

United States

UCLA, Los Angeles, California

UCSF, San Francisco, California

Sutter Health Network, San Pablo, California

FL Medical Clinic Orlando Health, Zephyrhills, Florida

Northwestern University, Chicago, Illinois

University Of Iowa, Iowa City, Iowa

Boston Medical Center, Boston, Massachusetts

Michigan Med University of Michigan, Ann Arbor, Michigan

University of Minnesota, Minneapolis, Minnesota

James Cancer Hospital, Columbus, Ohio

Oregon Health Sciences University, Portland, Oregon

Avera Cancer, Sioux Falls, South Dakota

LDS Hospital, Salt Lake City, Utah

Australia

Novartis Investigative Site, Camperdown, New South Wales

Novartis Investigative Site, Darlinghurst, New South Wales

Austria

Novartis Investigative Site, Graz

Novartis Investigative Site, Vienna

Brazil

Novartis Investigative Site, São Paulo, São Paulo

Czechia

Novartis Investigative Site, Olomouc

Novartis Investigative Site, Prague

Denmark

Novartis Investigative Site, Aarhus N

France

Novartis Investigative Site, Bordeaux

Novartis Investigative Site, Dijon

Novartis Investigative Site, Lille

Novartis Investigative Site, Lyon

Novartis Investigative Site, Montpellier

Novartis Investigative Site, Paris

Novartis Investigative Site, Rennes

Germany

Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg

Novartis Investigative Site, Göttingen, Lower Saxony

Novartis Investigative Site, Leipzig, Saxony

Novartis Investigative Site, Halle, Saxony-Anhalt

Novartis Investigative Site, Jena, Thuringia

Novartis Investigative Site, Berlin

Novartis Investigative Site, Mainz

Novartis Investigative Site, Nuremberg

Novartis Investigative Site, Ulm

Hungary

Novartis Investigative Site, Debrecen, Hajdu Bihar Megye

Novartis Investigative Site, Budapest

Israel

Novartis Investigative Site, Haifa

Novartis Investigative Site, Ramat Gan

Novartis Investigative Site, Tel Aviv

Italy

Novartis Investigative Site, Ancona, AN

Novartis Investigative Site, Bergamo, BG

Novartis Investigative Site, Brescia, BS

Novartis Investigative Site, Genova, GE

Novartis Investigative Site, Milan, MI

Novartis Investigative Site, Pescara, PE

Novartis Investigative Site, Perugia, PG

Novartis Investigative Site, Pisa, PI

Novartis Investigative Site, Pavia, PV

Novartis Investigative Site, Roma, RM

Novartis Investigative Site, Udine, UD

Japan

Novartis Investigative Site, Sapporo, Hokkaido

Novartis Investigative Site, Kanazawa, Ishikawa-ken

Novartis Investigative Site, Sendai, Miyagi

Novartis Investigative Site, Suita, Osaka

Novartis Investigative Site, Bunkyo-ku, Tokyo

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Kyoto

Netherlands

Novartis Investigative Site, Utrecht

Singapore

Novartis Investigative Site, Singapore

South Korea

Novartis Investigative Site, Seoul

Spain

Novartis Investigative Site, Santiago Compostela, A Coruna

Novartis Investigative Site, Santander, Cantabria

Novartis Investigative Site, Pamplona, Navarre

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Córdoba

Novartis Investigative Site, Madrid

Novartis Investigative Site, Málaga

Novartis Investigative Site, Salamanca

Novartis Investigative Site, Valencia

Switzerland

Novartis Investigative Site, Geneva

Novartis Investigative Site, Lausanne

Novartis Investigative Site, Zurich

Taiwan

Novartis Investigative Site, Taichung